Neuland Laboratories Limited (BOM: 524558)
India
· Delayed Price · Currency is INR
14,430
-365 (-2.47%)
At close: Dec 19, 2024
Neuland Laboratories Revenue
Neuland Laboratories had revenue of 3.11B INR in the quarter ending September 30, 2024, a decrease of -25.59%. This brings the company's revenue in the last twelve months to 15.28B, up 4.87% year-over-year. In the fiscal year ending March 31, 2024, Neuland Laboratories had annual revenue of 15.59B with 30.81% growth.
Revenue (ttm)
15.28B
Revenue Growth
+4.87%
P/S Ratio
11.67
Revenue / Employee
9.30M
Employees
1,643
Market Cap
178.35B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 15.59B | 3.67B | 30.81% |
Mar 31, 2023 | 11.91B | 2.40B | 25.20% |
Mar 31, 2022 | 9.52B | 147.07M | 1.57% |
Mar 31, 2021 | 9.37B | 1.73B | 22.64% |
Mar 31, 2020 | 7.64B | 965.74M | 14.47% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionNeuland Laboratories News
- 9 days ago - Mixed trends in November CDRMO exports, prefer Syngene and Neuland Labs over Divis Labs and Laurus Labs - Business Upturn
- 9 days ago - Neuland Labs exports surge threefold YoY in November, 43.1% MoM growth - Business Upturn
- 9 days ago - Neuland Labs shares down over 5% as 4.8 lakh shares worth Rs 747 crore change hands in block trade - Business Upturn
- 5 weeks ago - Neuland Laboratories shares surge nearly 10% amid AbbVie’s phase 2 setback on schizophrenia drug - Business Upturn
- 6 weeks ago - Goldman Sachs maintains buy on Neuland Labs, raises target to Rs 15,250; sees 7% upside potential - Business Upturn
- 6 weeks ago - Neuland Laboratories shares plunge over 13% after disappointing Q2 FY25 results; revenue down 25.1% YoY to ₹315.2 crore, PAT declines 64.1% - Business Upturn
- 6 weeks ago - Neuland Laboratories Q2 FY25 Results: Revenue down 25.1% YoY to ₹315.2 crore, PAT declines 64.1% - Business Upturn
- 7 weeks ago - Stocks to Buy This Diwali: AngelOne sees Neuland Laboratories reaching ₹19,580, with 25% growth potential - Business Upturn